Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

David Arthur Tuveson

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8017-2712; OpenAlex author ID A5072185005; NIH RePORTER profile ID 8586909. Sources: ClinicalTrials.gov.

Their work

Papers
123 (first author 9, last author 31)
Trials
1 (principal investigator on 1)
Grants
9
Labs led
2
Collaborators
454
Papers, trials and grants by year

2011: 2 papers, 1 trial · 2012: 8 papers, 1 grant · 2013: 5 papers · 2014: 6 papers · 2015: 6 papers · 2016: 12 papers · 2017: 6 papers, 1 grant · 2018: 8 papers, 1 grant · 2019: 13 papers · 2020: 13 papers · 2021: 7 papers, 1 grant · 2022: 8 papers, 1 grant · 2023: 4 papers · 2024: 8 papers · 2025: 7 papers, 1 grant · 2026: 10 papers, 3 grants

Papers 50 of 123

  1. Developmental and MAPK-responsive transcription factors regulate distinct malignant cell states and associated genetic dependencies in pancreatic cancer. Co-author DOI 10.1038/s41588-026-02714-8↗
  2. Computationally assisted patient finding for navigation to optimize pancreatic cancer care access. Co-author DOI 10.1093/oncolo/oyag037↗
  3. Implantable Microdevices for In Vivo Assessment of Chemotherapy Response in Patient Derived Organoid Orthotopic Pancreatic Cancer Models. Co-author DOI 10.1097/sla.0000000000007071↗
  4. Mitochondrial-Localized Keratin 17 Promotes Chemoresistance in Basal-like Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-4534↗
  5. MYC-Mediated USP39 Upregulation Stabilizes SRSF1 in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-25-1104↗
  6. Brain metastasis from KRAS wild-type pancreatic cancer and organoid correlates: a case report. Co-author DOI 10.21037/jgo-2025-aw-818↗
  7. AUM-302, a novel triple PIM/PI3K/mTOR inhibitor, synergizes with RAS inhibition and impedes the growth of pancreatic ductal adenocarcinoma spheroids and organo… Co-author DOI 10.3389/fphar.2026.1685433↗
  8. Frizzled 6 Drives EMT and Stromal Remodeling Downstream of SP1 in Basal-like Pancreatic Cancer Co-author DOI 10.64898/2025.12.31.697213↗
  9. Extra-lineage tissue programs define the transcription states of human pancreatic cancer Co-author DOI 10.64898/2026.04.29.721655↗
  10. Multimodal Machine Learning for Predicting Outcomes in the PASS-01 Trial of Systemic Therapy for Metastatic Pancreatic Cancer Co-author DOI 10.64898/2026.08.24.26360900↗
  11. MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. Co-author DOI 10.1038/s41586-025-08721-9↗
  12. Macrophages and fibroblasts as regulators of the immune response in pancreatic cancer. First author DOI 10.1038/s41590-025-02134-6↗
  13. Signal peptide-independent secretion of keratin-19 by pancreatic cancer cells. Co-author DOI 10.1073/pnas.2426218122↗
  14. GATA6 Amplification Is Associated With Improved Survival in TP53-Mutated Unresectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002431↗
  15. FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development. Last author DOI 10.1158/0008-5472.can-24-4576↗
  16. PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Panc… Co-author DOI 10.1200/jco-25-00436↗
  17. Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metast… Co-author DOI 10.1200/jco-25-02195↗
  18. Engrailed-1 Promotes Pancreatic Cancer Metastasis. Co-author DOI 10.1002/advs.202308537↗
  19. Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer. Co-author DOI 10.1038/s41591-024-03075-7↗
  20. Pancreatic cancer-associated fibroblasts modulate macrophage differentiation via sialic acid-Siglec interactions. Co-author DOI 10.1038/s42003-024-06087-8↗
  21. Cytidine deaminases APOBEC3C and APOBEC3D promote DNA replication stress resistance in pancreatic cancer cells. Co-author DOI 10.1038/s43018-024-00742-z↗
  22. The evolving role for surgery in pancreatic cancer. Co-author DOI 10.1093/carcin/bgae062↗
  23. Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC. Co-author DOI 10.1136/gutjnl-2023-329807↗
  24. A mucus production programme promotes classical pancreatic ductal adenocarcinoma. Last author DOI 10.1136/gutjnl-2023-329839↗
  25. Scribble Deficiency Promotes Pancreatic Ductal Adenocarcinoma Development and Metastasis. Co-author DOI 10.1158/0008-5472.can-23-3419↗
  26. A TEAD2-Driven Endothelial-Like Program Shapes Basal-Like Differentiation and Metastasis of Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2023.02.049↗
  27. p73 activates transcriptional signatures of basal lineage identity and ciliogenesis in pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2023.04.20.537667↗
  28. Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-22-1013↗
  29. Plasma cells in human pancreatic ductal adenocarcinoma secrete antibodies against self-antigens. Co-author DOI 10.1172/jci.insight.172449↗
  30. Lead identification using 3D models of pancreatic cancer. Co-author DOI 10.1016/j.slasd.2022.03.002↗
  31. ICGC-ARGO precision medicine: familial matters in pancreatic cancer. Co-author DOI 10.1016/s1470-2045(21)00703-8↗
  32. BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signali… Co-author DOI 10.1038/s41467-022-34081-3↗
  33. Pancreatic Cancer Patient-derived Organoids Can Predict Response to Neoadjuvant Chemotherapy. Co-author DOI 10.1097/sla.0000000000005558↗
  34. Loss of p53 tumor suppression function drives invasion and genomic instability in models of murine pancreatic cancer Last author DOI 10.1101/2021.12.31.472823↗
  35. SPDEF promotes the classical subtype of pancreatic ductal adenocarcinoma Last author DOI 10.1101/2022.03.18.484951↗
  36. Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer. Co-author DOI 10.1136/jitc-2021-003549↗
  37. Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response. Co-author DOI 10.1158/1078-0432.ccr-21-4165↗
  38. Single-Pass vs 2-Pass Endoscopic Ultrasound-Guided Fine-Needle Biopsy Sample Collection for Creation of Pancreatic Adenocarcinoma Organoids. Co-author DOI 10.1016/j.cgh.2020.02.045↗
  39. Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade. Co-author DOI 10.1038/s41467-021-23731-7↗
  40. Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression. Co-author DOI 10.1053/j.gastro.2021.06.045↗
  41. Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer. Last author DOI 10.1073/pnas.2016904118↗
  42. Loss of KRAS G12D feedback regulation involving splicing factor SRSF1 accelerates pancreatic cancer Co-author DOI 10.1101/2021.10.13.464210↗
  43. Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA. Co-author DOI 10.1158/1078-0432.ccr-20-2475↗
  44. Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3715↗
  45. Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2019.12.012↗
  46. Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-020-0846-2↗
  47. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Co-author DOI 10.1038/s41588-019-0566-9↗
  48. Author Correction: Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Co-author DOI 10.1038/s41588-020-0588-3↗
  49. SOAT1 promotes mevalonate pathway dependency in pancreatic cancer. Last author DOI 10.1084/jem.20192389↗
  50. Pancreatic cancer SLUGged. First author DOI 10.1084/jem.20200819↗

Trials 1

  1. Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS) Principal investigator NCT01096732↗

Grants 9

  1. CSHL Cancer Center Support Grant P30CA045508↗
  2. SOAT1 as a targetable dependency in Pancreatic Adenocarcinoma R01CA292775↗
  3. Discovery of Natural Products and Natural Product Derivatives as Inhibitors of KLK6 to Prevent the Progression of Preneoplastic Ductal Pancreatic Cancer UG3CA290364↗
  4. Fibroblast Heterogeneity in Pancreatic Cancer R01CA249002↗
  5. CSHL-JAX Patient-Derived Models of Pancreatic Cancer as Systems for Investigating Tumor Heterogeneity U01CA224013↗
  6. Nrf2 Regulation of Ductal Pancreatic Cancer Etiology and Treatment Response R01CA188134↗
  7. Pilot 2: Organoids to investigate Pancreatic Cancer in under represented minorities P20CA192996↗
  8. (PQA-4) Organoid Omics To Detect And Defeat Ductal Pancreatic Cancer R01CA190092↗
  9. Lustgarten Pancreatic Cancer Research Laboratory at Cold Spring Harbor Laboratory (Tuveson Lab) AWARD lustgarten:2012-david-tuveson-lustgarten-pancreatic-cancer-research-la

Closest collaborators

The 25 strongest of 454 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Youngkyu Park · 24 shared papers, 2015–2026 · strength 2.98
  2. John Edward Moses · 2 shared grants, 2026 · strength 2.52
  3. Faiyaz Notta · 11 shared papers, 2020–2026 · strength 1.66
  4. Hervé Tiriac · 20 shared papers, 2014–2024 · strength 1.62
  5. Daniel A. King · 8 shared papers, 2022–2026 · strength 1.49
  6. Christopher R. Vakoc · 11 shared papers, 2017–2024 · strength 1.35
  7. Steve Gallinger · 10 shared papers, 2017–2026 · strength 1.27
  8. Kenneth H. Yu · 10 shared papers, 2015–2026 · strength 1.21
  9. Giulia Biffi · 12 shared papers, 2015–2024 · strength 1.15
  10. Linda Van Aelst · 1 shared paper, 1 shared grant, 2021–2026 · strength 1.12
  11. Claudia Tonelli · 7 shared papers, 2019–2025 · strength 1.09
  12. Grainne Mary O'Kane · 7 shared papers, 2020–2026 · strength 1.03
  13. CHRISTOPHER Martin HAMMELL · 1 shared grant, 2026 · strength 1.00
  14. Lindsey A. Baker · 10 shared papers, 2015–2020 · strength 0.97
  15. Chang‐Il Hwang · 11 shared papers, 2015–2024 · strength 0.94
  16. Robert C. Grant · 6 shared papers, 2020–2026 · strength 0.86
  17. Jennifer Jane Knox · 6 shared papers, 2020–2026 · strength 0.86
  18. Elizabeth M. Jaffee · 6 shared papers, 2019–2026 · strength 0.80
  19. Albrecht Neeße · 14 shared papers, 2011–2024 · strength 0.76
  20. Daniel Öhlund · 9 shared papers, 2015–2024 · strength 0.75
  21. Erica S. Tsang · 4 shared papers, 2025–2026 · strength 0.72
  22. Tobiloba E. Oni · 9 shared papers, 2015–2021 · strength 0.70
  23. Paul Robson · 1 shared grant, 2022 · strength 0.66
  24. Dannielle D. Engle · 12 shared papers, 2014–2019 · strength 0.66
  25. Fieke E. M. Froeling · 5 shared papers, 2018–2025 · strength 0.64

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.